Amgen to buy Celgene psoriasis drug for $13.4 billion

You are here: Home > Biotech > Current Article

Amgen’s stock climbs after announcing Otezla acquisition

By Marissa Nall / Monday, August 26th, 2019 / Comments Off on Amgen’s stock climbs after announcing Otezla acquisition

A statue of Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. Story updated at 4 p.m. Aug. 26: Shares for the region’s biotech heavyweight popped 3 percent Aug. 26 after it announced plans to add a psoriasis drug to its portfolio. Amgen said it will spend $13.4 billion in cash…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.